

TABLE OF CONTENTS

Description		Page No.
	List of figures	i-ii
	List of tables	iii
	Abbreviations & symbols	iv-vii
	Preface	vii-xi
Chapter 1: Introduction		1-34
1	Cancer	1
1.2	Types of cancer	2
1.3	Metastasis and invasive properties of cancer cells	3
1.4	Process of Carcinogenesis	4
1.5	Cell proliferation	5
1.6	Cell cycle and growth regulation	5
1.7	Cell cycle network	6
1.8	Cellular signalling pathways	7
1.9	Intracellular signalling pathways	7
1.10	Apoptosis pathway in cancer	7
1.10.1	The extrinsic pathway	9
1.10.2	The intrinsic pathway	9
1.11	Receptor tyrosine kinases	10
1.11.1	Regulation of receptor tyrosine kinases	12
1.11.2	Tyrosine autophosphorylation	12
1.12	Non receptor tyrosine kinases	12
1.12.1	Regulation of nonreceptor tyrosine kinases	13
1.13	Epidermal growth factor receptor(EGFR) pathway	13
1.13.1	Mechanism of EGFR signalling activation	14
1.13.2	EGFR targeted therapy	15
1.14	Vascular endothelial growth factor	15

1.14.1	VEGF-mediated functions in tumor cells	16
1.15	Inhibition of the Hedgehog pathway	17
1.16	Approaches For The Treatment of Cancer	17
1.16.1	Alkylating Agents	17
1.16.2	Antimetabolites	18
1.16.3	Platinum Compounds	19
1.16.4	Topoisomerase Inhibitors	19
1.16.5	Plant Alkaloids	21
1.17	Novel Approaches to Anticancer Drug Discovery	22
1.17.1	Signal transduction Inhibitors	22
1.17.2	Tyrosine Kinase Inhibitors	22
1.17.3	Cell Cycle Regulators	23
1.17.4	Inhibitors Acting Through the Apoptosis Pathway	24
1.17.5	Angiogenesis Inhibitors	25
1.18	Recent Developments in Anticancer Drug Design	27
1.18.1	Drug Design	27
1.18.2	Structure-Based Drug Design (SBDD)	27
1.18.3	Docking	27
1.18.4	Approaches for the Docking	29
1.19	Quinones	30
1.20	Naphthoquinone	30
1.21	Factors affecting cancer and naphthoquinone-based anticancer drugs	32
1.21.1	Oxidative stress	32
1.21.2	Reactive oxygen species (ROS)	33
1.21.3	Level of ROS in cancer cell versus normal cell	33

1.21.4	Mechanism of cell death involving quinone	33
1.22	Modification of Signal Transduction by Quinones	34
1.23	Quinone as a Michael acceptor	34
1.24	Quinones as Electron Transfer Agents	34
Chapter 2: Review of Literature		36-63
2.1	Quinone, a promising lead for diverse drug development and formulation	36
2.2	1,4-Naphthoquinones as anticancer agents	36
2.3	1, 4-Naphthoquinones as anti-tubercular agents	51
2.4	1, 4-Naphthoquinones as antimalarial	52
2.5	1, 4-Naphthoquinones as antifungal	53
2.6	1, 4-Naphthoquinones as antibacterial	55
2.7	1, 4-Naphthoquinones as anti-trypanosomal	57
2.8	1, 4-Naphthoquinones as anti-inflammatory	60
2.9	1, 4-Naphthoquinones as antiviral	61
2.10	1, 4-Naphthoquinones as miscellaneous	62
Chapter 3: Rationale, Objective and Plan of Work		64-71
3.1	Rationale and objective	64
3.2	Design of 1, 4-Naphthoquinone derivatives	68
3.3	Plan of work	70
3.4	Design and synthesis of: series 1 and series 2	70
3.5	Characterization of synthesized compounds	70
3.6	<i>In-silico</i> study	70
3.7	Biological evaluation	71
Chapter 4: Experimental		72-83
4	Chemistry	72
4.1	Instrumentation, Chemicals and solvents	72
4.2	Method for the Synthesis of 3-((3-methyl-1, 4-dioxo-1, 4-	72

	dihydro naphthalen-2-yl) thio) propanoic acid (3)	
4.3	Method for the Synthesis of Compounds MB-1 to MB-19 (Series I)	73
4.4	Method for the Synthesis of Compounds MB-20 to MB-33 (Series II)	73
4.5	Characterization of Synthesized Compounds	74
4.5.1	Physicochemical Characterization	75
4.5.2	Spectral characterization and elemental analysis	75
4.6	Computer Aided Drug Design (CADD) Studies	76
4.6.1	Molecular Docking Studies	76
4.6.2	<i>In-Silico</i> Pharmacokinetic Studies	77
4.7	Cell culture	78
4.7.1	<i>In-vitro</i> Cytotoxicity screening	79
4.8	<i>In-vitro</i> EGFR tyrosine kinase inhibitory activity	80
4.9	<i>In-vivo</i> anticancer activity	80
4.9.1	Animals and maintenance	81
4.9.2	Estimation of acute toxicity and LD ₅₀ determination	81
4.9.3	Induction of mammary carcinomas	82
4.9.4	<i>In-vivo</i> antitumor efficacy	82
4.10	Statistical analysis	83
<hr/> Chapter 5: Results and Discussions		84-123
5	Chemistry	84
5.1	2-((3-(4-substituted-piperazin-1-yl)-3-oxopropyl)thio)naphthalene-1,4- dione (Series I)	84
5.2	Characterization of Piperazine Substituted 1, 4-Naphthoquinone	84
5.3	Spectral Characterization	88
5.4	Characterization of Oxadiazoles substituted 1,4-Naphthoquinone (Series II)	97

5.5	Molecular Docking	107
5.6	<i>In-Silico</i> Pharmacokinetic Studies	112
5.7	Pharmacological evaluation	114
5.7.1	<i>In-vitro</i> anticancer activity	114
5.8	<i>In-vitro</i> EGFR kinase inhibition	117
5.9	<i>In-vivo</i> Anticancer Activity Evaluation	119
Chapter 6: Summary and Conclusion		124-127
6.1	Summary and conclusion	124
7	Chapter 7: References	128-142
8	Appendix	144-147